On March 19, 2026, Seattle-based biopharmaceutical firm Atossa Therapeutics officially announced the addition of two key figures to its clinical leadership team. Kathy Puyana Theall, MD, and Adebola Giwa, MD, will take on executive roles overseeing the company’s primary programs.
Details of the appointments and development goals:
-
Breast Oncology Expert: Kathy Puyana Theall, MD, has been named Medical Director—Breast Oncology. Bringing extensive experience from Pfizer and Stemline-Menarini, she previously made significant contributions to the clinical development of the blockbuster cancer drug Ibrance. She will lead late-stage oncology development and regulatory approvals.
-
Rare Diseases Expert: Adebola Giwa, MD, takes the role of Medical Director—Rare Diseases. He possesses deep expertise in endocrine and rare disease clinical development, focusing on conditions such as McCune-Albright syndrome and Duchenne muscular dystrophy.
-
Lead Candidate Focus: These appointments are designed to accelerate the clinical and regulatory roadmap for Atossa’s lead product candidate, (Z)-Endoxifen. This compound is currently being evaluated across multiple clinical settings.
-
Corporate Vision: According to Atossa leadership, the combined nearly 40 years of industry experience from the two new directors will significantly enhance the company’s ability to execute its development strategy and build a world-class clinical organization.